Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Pfizer Inc. PFE on Wednesday shared topline results from the late-stage study of its cancer treatment, ELREXFIO (elranatamab) ...

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...

Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...

Pfizer Inc. (NYSE: PFE) will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 – June 2, ...

Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs. The Big Pharma evaluated three ...

Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their ...

Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated ...

Good day, everyone, and welcome to Pfizer's Fourth Quarter 2025 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, Chief ...

A new Lyme disease vaccine made by Pfizer and Valneva could lower infection rates of the tick-borne illness, but federal approval and patient uptake could be a challenge ...